LCTX
Lineage Cell Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Lineage Cell Therapeutics has 8 disclosed suppliers and 4 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceIndependent Registered Public Accounting Firm - Audit Opinion Baker Tilly US, LLP (PCAOB # 23 )
LCTX 10-Kaccession 0001193125-26-093992
SentenceLineage and CRT effectuated the option by simultaneously entering into a license agreement (the "CRT License Agreement") pursuant to which Lineage paid a signature fee of £ 1,250,000 (approximately $ 1.6 million based upon exchange rates in effect when the fee was paid).
LCTX 10-Kaccession 0001193125-26-093992
SentenceAll of our manufacturing processes, including cell banking and product manufacturing for our cell therapy product candidates, are conducted by our subsidiary, CCN, at its facility in Jerusalem, Israel, and more than two-thirds of our workforce are CCN employees based in that facility.
LCTX 10-Kaccession 0001193125-26-093992
SentenceThe clinical development of OPC1 has been supported in part by $14.3 million of funding from CIRM, a state agency established to fund stem cell research and development of new stem cell-based treatments.
LCTX 10-Kaccession 0001193125-26-093992
SentenceLineage continues to make royalty payments to Geron from royalties generated from these patents.
LCTX 10-Kaccession 0001193125-26-093992
SentenceIn December 2025, CCN accrued a payment obligation to be funded by Lineage due to Hadasit for 21.5% of the $5.0 million received from Roche upon the achievement of the first milestone under the Roche Agreement.
LCTX 10-Kaccession 0001193125-26-093992
SentenceOn March 3, 2026, we entered into an Amended and Restated Non-Exclusive License Agreement (the "A&R WARF License Agreement") with the Wisconsin Alumni Research Foundation ("WARF").
LCTX 10-Kaccession 0001193125-26-093992
SentenceThe $5.5 million increase in collaboration revenue was driven by: (i) the achievement of the first milestone under the Roche Agreement in the amount of $5.0 million whereby $4.6 million was recognized as revenue in 2025; (ii) $2.5 million in revenue from our research collaboration agreement with WDI signed in 2025; (iii) an approximate $0.7 million increase in revenue related to the remaining deferred revenue recognized upon the termination of the license agreement with Immunomic Therapeutics, Inc. in 2025, partially offset by (iv) approximately $2.4 million in lower revenue recognized from deferred revenue under the Roche Agreement.
LCTX 10-Kaccession 0001193125-26-093992
SentenceThe $5.5 million increase in collaboration revenue was driven by: (i) the achievement of the first milestone under the Roche Agreement in the amount of $5.0 million whereby $4.6 million was recognized as revenue in 2025; (ii) $2.5 million in revenue from our research collaboration agreement with WDI signed in 2025; (iii) an approximate $0.7 million increase in revenue related to the remaining deferred revenue recognized upon the termination of the license agreement with Immunomic Therapeutics, Inc. in 2025, partially offset by (iv) approximately $2.4 million in lower revenue recognized from deferred revenue under the Roche Agreement.
LCTX 10-Kaccession 0001193125-26-093992
SentenceAs a result, and subject to the requirements of the Innovation Law, we paid the IIA approximately 24.1% of the upfront payment we received under the Roche Agreement, or approximately $12.1 million, and we are obligated to pay to the IIA approximately 24.1% of any milestone and royalty payments we may receive under the Roche Agreement, up to an aggregate cap on all payments to the IIA, such cap growing over time via interest accrual until paid in full.
LCTX 10-Kaccession 0001193125-26-093992
SentenceThe $5.5 million increase in collaboration revenue was driven by: (i) the achievement of the first milestone under the Roche Agreement in the amount of $5.0 million whereby $4.6 million was recognized as revenue in 2025; (ii) $2.5 million in revenue from our research collaboration agreement with WDI signed in 2025; (iii) an approximate $0.7 million increase in revenue related to the remaining deferred revenue recognized upon the termination of the license agreement with Immunomic Therapeutics, Inc. in 2025, partially offset by (iv) approximately $2.4 million in lower revenue recognized from deferred revenue under the Roche Agreement.
LCTX 10-Kaccession 0001193125-26-093992
Largest filed tie
—
Lineage Cell Therapeutics, Inc.
1.01
Expected move
No implied move.